Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director · President, CEO | March 12, 2026 | August 07, 2026 |
| First Tracks Biotherapeutics, Inc.TRAX · Entity 4696 | Director · President, CEO | August 15, 2026 | August 18, 2026 |
| Mirati Therapeutics, Inc.MRTX · Entity 94908 | EVP, Chief Operating Officer | February 02, 2021 | February 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date March 12, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 53,334 |
Reported balance
After 2026-03-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-12 · Grant · Acquired 53,334 · Balance 53,334 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date.
First Tracks Biotherapeutics, Inc.
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 440,485 |
Reported balance
After 2026-08-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-15 · Grant · Acquired 193,575 · Balance 440,485 F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026.
F2: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock.
F3: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date.
Mirati Therapeutics, Inc.
Report date February 02, 2021 · Filed February 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,638 |
Ending reported balance
After 2021-02-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-02 · Exercise / conversion · Acquired 1,340 · Balance 31,978 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. Row 2 · 2021-02-02 · Sale · Disposed 1,340 · Balance 30,638 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. |
| Non Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $114.33 · Expires 2030-01-05 | Direct | 63,630 |
Reported balance
After 2021-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-02 · Exercise / conversion · Disposed 1,340 · Balance 63,630 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F2: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.
F2: 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 38,828 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 26,250 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 14,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.62 · Expires 2026-05-01 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-17 · Disposition to issuer · Disposed 21,500 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 15, 2026 Filed Aug 18, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantPerformance Stock Units · Derivative | 193,575 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000017 · form4-08182026_040802.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,485 Underlying: Common Stock · 193,575 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 15, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on August 15, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| August 02, 2026 Filed Aug 5, 2026 22:24 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantPerformance Stock Units · Derivative | 193,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000014 · form4-08052026_100851.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,156 Underlying: Common Stock · 193,576 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on August 2, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on August 2, 2027 and 50% vests on July 1, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 271,100 | $0.00 Strike: $17.81 | $0.00 |
DisclosureSEC source: 0001673528-26-000013 · form4-05142026_040507.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 271,100 Underlying: Common Stock · 271,100 shares Expires 2036-05-11 F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on May 12, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · balance_after: In addition to the options to purchase a total of 271,100 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 1,035,941 shares of common stock, which options vest according to their terms. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 100,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000013 · form4-05142026_040507.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,200 Underlying: Common Stock · 100,200 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F2 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on May 12, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 133,400 | $0.00 Strike: $32.17 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 14 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,400 Underlying: Common Stock · 133,400 shares Expires 2036-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F6 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 133,400 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 13 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,400 Underlying: Common Stock · 133,400 shares Expires 2036-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F6 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 305,500 | $0.00 Strike: $10.87 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 12 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,500 Underlying: Common Stock · 305,500 shares Expires 2035-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 305,500 | $0.00 Strike: $14.83 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 11 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,500 Underlying: Common Stock · 305,500 shares Expires 2035-01-06 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 379,620 | $0.00 Strike: $15.53 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 10 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,620 Underlying: Common Stock · 379,620 shares Expires 2034-01-02 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 379,620 | $0.00 Strike: $21.19 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 9 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,620 Underlying: Common Stock · 379,620 shares Expires 2034-01-02 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 194,900 | $0.00 Strike: $17.02 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 8 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,900 Underlying: Common Stock · 194,900 shares Expires 2033-01-05 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 194,900 | $0.00 Strike: $23.23 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 7 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,900 Underlying: Common Stock · 194,900 shares Expires 2033-01-05 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $22.31 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 6 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $30.44 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 2,321 | $0.00 Strike: $22.80 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 4 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,321 Underlying: Common Stock · 2,321 shares Expires 2031-11-25 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 2,321 | $0.00 Strike: $31.12 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,321 Underlying: Common Stock · 2,321 shares Expires 2031-11-25 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $22.80 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-11-25 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:33 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $31.12 | $0.00 |
DisclosureSEC source: 0001673528-26-000011 · form4-04222026_100425.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,510 Underlying: Common Stock · 16,510 shares Expires 2031-11-25 F1 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire AnaptysBio shares of common stock in an amount determined in accordance with the Separation Agreement. F2 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 98,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 12 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,600 Underlying: Common Stock · 98,600 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F9 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit ("RSU") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F13 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F13 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 80,512 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 11 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,512 Underlying: Common Stock · 80,512 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F9 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit ("RSU") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F12 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F12 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 69,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 10 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,355 Underlying: Common Stock · 69,355 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F9 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit ("RSU") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F11 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F11 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantRestricted Stock Unit · Derivative | 17,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 9 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,850 Underlying: Common Stock · 17,850 shares Expires not disclosed F8 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F9 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation Agreement, each outstanding restricted stock unit ("RSU") with respect to AnaptysBio shares of common stock was adjusted so that such RSU became an RSU with respect to First Tracks shares of common stock and an RSU with respect to AnaptysBio's shares of common stock. As a result, the Reporting Person acquired RSUs with respect to First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F10 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F10 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 133,400 | $0.00 Strike: $11.75 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 8 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,400 Underlying: Common Stock · 133,400 shares Expires 2036-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F7 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 305,500 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 7 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,500 Underlying: Common Stock · 305,500 shares Expires 2035-01-06 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F6 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 7, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 379,620 | $0.00 Strike: $5.67 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 6 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 379,620 Underlying: Common Stock · 379,620 shares Expires 2034-01-02 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 3, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 194,900 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,900 Underlying: Common Stock · 194,900 shares Expires 2033-01-05 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F4 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 9,200 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 4 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,200 Underlying: Common Stock · 9,200 shares Expires 2032-02-09 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 2,321 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,321 Underlying: Common Stock · 2,321 shares Expires 2031-11-25 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:05 UTC | First Tracks Biotherapeutics, Inc. TRAX · Entity 4696 | GrantEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001673528-26-000010 · form4-04222026_040401.xml · derivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-11-25 F2 · kind: Effective as of a pro rata distribution by AnaptysBio to holders of its shares of common stock pursuant to the Separation and Distribution Agreement dated as of April 20, 2026, by and between AnaptysBio and First Tracks (the "Separation Agreement"), each outstanding option to acquire AnaptysBio shares of common stock was adjusted so that such option became an option to acquire First Tracks shares of common stock and an option to acquire AnaptysBio shares of common stock. As a result, the Reporting Person acquired options to acquire First Tracks shares of common stock in an amount determined in accordance with the Separation Agreement. F3 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| April 20, 2026 Filed Apr 23, 2026 22:07 UTC Amendment | ANAPTYSBIO, INC ANAB · Entity 4640 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $31.12 | $0.00 |
DisclosureSEC source: 0001673528-26-000012 · form4a-04232026_100429.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2031-11-25 F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 100 | $65.99 | $6,599.00 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 11 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 495,965 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,038 | $65.20 | $198,072.13 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 10 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 496,065 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F12 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.785 to $65.61 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,155 | $64.19 | $202,522.29 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 9 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 499,103 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F11 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.71 to $64.64 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,592 | $63.35 | $164,203.98 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 8 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 502,258 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F10 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.71 to $63.685 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 1,012 | $62.15 | $62,898.33 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 7 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 504,850 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F9 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.66 to $62.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 550 | $60.63 | $33,344.52 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 6 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,862 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F8 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.405 to $61.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 490 | $59.62 | $29,215.61 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 5 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,412 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F7 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.29 to $60.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 3,662 | $58.62 | $214,651.06 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 4 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,902 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F6 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.29 to $59.275 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 2,570 | $57.91 | $148,819.19 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 3 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 510,564 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.29 to $58.21 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 27, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 510 | $56.61 | $28,872.63 |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,134 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.285 to $57.215 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2026 Filed Mar 28, 2026 00:15 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantCommon Stock | 34,300 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001673528-26-000007 · form4-03282026_120340.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 513,644 F1 · shares: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 25, 2026. F2 · price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 12, 2026 Filed Aug 7, 2026 21:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantPerformance Stock Units · Derivative | 53,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000016 · form4-08072026_090814.xml · derivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,334 Underlying: Common Stock · 53,334 shares Expires not disclosed F1 · security: Represents performance-based restricted stock units ("PSUs") that were earned by the Reporting Person upon the achievement of certain performance criteria as certified by the Compensation Committee of the Issuer's Board of Directors on March 12, 2026. F2 · derivative.exercise_price: Each PSU represents a conditional right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. F3 · derivative.expiration_date: The PSUs vest and settle over two years; 50% vests on March 12 2027 and 50% vests on March 12, 2028, subject to the continuing service of the Reporting Person on each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 10, 2026 00:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 14,281 | $44.71 | $638,503.51 |
DisclosureSEC source: 0001673528-26-000006 · form4-01102026_120114.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,344 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 21:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | SaleCommon Stock | 9,202 | $45.11 | $415,102.22 |
DisclosureSEC source: 0001673528-26-000004 · form4-01082026_090111.xml · nonDerivative · entry 2 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,787 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 26,838 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000006 · form4-01102026_120114.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,512 Underlying: Common Stock · 26,838 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 7, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 07, 2026 Filed Jan 10, 2026 00:12 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 26,838 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001673528-26-000006 · form4-01102026_120114.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 493,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantStock Option (right to buy) · Derivative | 133,400 | $0.00 Strike: $43.91 | $0.00 |
DisclosureSEC source: 0001673528-26-000004 · form4-01082026_090111.xml · derivative · entry 5 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,400 Underlying: Common Stock · 133,400 shares Expires 2036-01-05 F5 · derivative.exercise_date: The stock option vests as to 25% of the total shares on January 6, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | GrantRestricted Stock Unit · Derivative | 98,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000004 · form4-01082026_090111.xml · derivative · entry 4 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,600 Underlying: Common Stock · 98,600 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F4 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2027 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionRestricted Stock Unit · Derivative | 17,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001673528-26-000004 · form4-01082026_090111.xml · derivative · entry 3 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,850 Underlying: Common Stock · 17,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. F3 · derivative.expiration_date: The RSUs vests as to 25% of the total RSUs annually commencing on January 6, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:10 UTC | ANAPTYSBIO, INC ANAB · Entity 4640 | Exercise / conversionCommon Stock | 17,850 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001673528-26-000004 · form4-01082026_090111.xml · nonDerivative · entry 1 Faga Daniel · CIK 0001673528 · Director · President, CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 475,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.